Points of Order

Debate between Crispin Blunt and Chris Philp

Monday 22nd May 2023 Commons Chamber

[Chris Philp]

Further to that point of order, Madam Deputy Speaker. Very briefly, I regret that I was not in Parliament at the time of the debate. I did give my hon. Friend the Member for Reigate (Crispin Blunt) advance notice of that. I was at the defence establishment in Porton Down at the time. As often happens, another Home Office Minister, the Minister for Immigration—a very capable Home Office Minister—replied. I have previously met one to one with the hon. Member for Warrington North (Charlotte Nichols) to discuss this in detail, and I replied to an Adjournment debate just a few weeks ago. As I said at the time, I have, subsequent to the debate and the meeting, asked the Advisory Council on the Misuse of Drugs to accelerate its work on removing barriers to research for all schedule 1 drugs, including psilocybin. So I take this opportunity to assure my hon. Friend that I have asked for that work to be accelerated, and the calls that he and other Members have made have been heard.

[Crispin Blunt]

rose—

Proscribed Psychedelic Drugs

Debate between Crispin Blunt and Chris Philp

Tuesday 14th March 2023 Commons Chamber

[The Minister for Crime, Policing and Fire (Chris Philp)]

In the short time that I have available, I thank my hon. Friend the Member for Reigate (Crispin Blunt) for securing the debate and for the thoughtful, knowledgeable and carefully considered manner in which he delivered his speech. I also recognise the hon. Member for Warrington North (Charlotte Nichols), who is in her place. I know that she has a deep personal interest in the topic, about which we had a detailed meeting a few days ago, so I am delighted to see her in the Chamber.

Of course, the Department of Health and Social Care leads on questions concerning the availability of medicines and prescribing, because medicines are licensed and regulated by the MHRA. The Home Office, however, is responsible for controlled drugs legislation and our controlled drugs licensing regime to support research and clinical trials in the UK, which is why I am responding rather than a Health Minister.

I am keen to encourage research into the use of drugs in the UK as far as we can. We have an internationally well-regarded research sector in universities and, of course, in commercial pharmaceutical companies. It can be a great source of national competitive advantage to make their research projects as straightforward as possible.

Drugs scheduled in schedule 1 can be used for research purposes, but with a licence. As I discussed with the hon. Member for Warrington North a few days ago, I know that some people feel that the process to obtain such a licence can be onerous, particularly for universities and NHS trusts. Clearly, for drugs scheduled in schedule 2 and higher, those restrictions do not apply in the same way. I am very aware of the point about research.

I am also aware that, to consider whether there are medical benefits that would support the rescheduling of drugs from schedule 1 to schedule 2 or higher, which might enable them to be prescribed to patients for medical purposes, there needs to be a research base. I accept that there is an element of chicken and egg or Catch-22 about the situation, because we need to do the research before there is an evidence base to justify the rescheduling that might be merited.

As my hon. Friend the Member for Reigate said, I received part 1 of the Advisory Council on the Misuse of Drugs’ advice on reducing barriers to research with controlled drugs, which focused on synthetic cannabinoids. In December last year, so just a few weeks ago, I formally commissioned it to conduct part 2 of its review, which is designed and intended to consider, and will consider, research with schedule 1 drugs more widely. That of course includes LSD and MDMA. In my letter to the ACMD commissioning that work, I specifically highlighted psilocybin. It would be open to the Government, depending on the ACMD’s advice, to change the research rules to say that all schedule 1 drugs might be capable of being used for research purposes without the onerous requirements that currently apply, in the same way as happens with schedule 2 drugs and higher, or some variation of that. There is obviously quite a lot of policy detail that one would have to consider, but were that move to be made, it would clearly address the barriers to research that my hon. Friend highlighted. Were those barriers to research to be removed, the evidence base could then be developed, which might provide a basis for the MHRA to make a case that such a drug should be moved to schedule 2 or higher, and that would facilitate doctors prescribing these drugs to the patients who need them.

My hon. Friend very kindly said that he would not press me too hard, given that I am relatively new in this position. I think the comments I have made do suggest that there is a path forward. I do strongly support making it as easy as possible for UK institutions—universities, hospitals and private companies—to conduct research using not just psilocybin, but all drugs, and there is clearly a commercial as well as an academic benefit. I am looking forward to receiving the ACMD advice as soon as possible, and I can certainly assure my hon. Friend, the hon. Member for Warrington North and others that, when that is received, it will receive my prompt and positive attention.

[Crispin Blunt]

Will the Minister give way?

[Chris Philp]

I think you are indicating that we are almost out of time, Mr Deputy Speaker, but I am sure my hon. Friend and I can speak briefly afterwards, and on that point, I will rest.

Question put and agreed to.

Independent Cultural Review of London Fire Brigade

Debate between Crispin Blunt and Chris Philp

Monday 28th November 2022 Commons Chamber

[Chris Philp]

The right hon. Lady is nodding, so I am happy to raise that point again and see whether publication can be expedited.

[Crispin Blunt (Reigate) (Con)]

May I say how welcome it is that Commissioner Andy Roe commissioned this report and is finally leading and gripping this problem? We know that the Fire Brigades Union is particularly strong within the fire service across the country. What evidence is there of the FBU’s role in reinforcing or challenging this culture?

[Chris Philp]

As of when I came over today from the Home Office, I do not think the FBU had published or put out a formal statement responding to the report, so I am sure my hon. Friend and others in the House will study its report or respond carefully when it chooses to put one out.